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Abstract
Background: Antibiotics are preferentially delivered via the peritoneal route to treat peritonitis,
a major complication of peritoneal dialysis (PD), so that maximal concentrations are delivered at
the site of infection. However, drugs administered intraperitoneally can be absorbed into the
systemic circulation. Drugs excreted by the kidneys accumulate in PD patients, increasing the risk
of toxicity. The aim of this study is to examine a model of gentamicin pharmacokinetics and to
develop an intraperitoneal drug dosing regime that maximises bacterial killing and minimises
toxicity.
Methods/Design: This is an observational pharmacokinetic study of consecutive PD patients
presenting to the Royal Brisbane and Women's Hospital with PD peritonitis and who meet the
inclusion criteria. Participants will be allocated to either group 1, if anuric as defined by urine output
less than 100 ml/day, or group 2: if non-anuric, as defined by urine output more than 100 ml/day.
Recruitment will be limited to 15 participants in each group. Gentamicin dosing will be based on
the present Royal Brisbane & Women's Hospital guidelines, which reflect the current International
Society for Peritoneal Dialysis Peritonitis Treatment Recommendations. The primary endpoint is
to describe the pharmacokinetics of gentamicin administered intraperitoneally in PD patients with
peritonitis based on serial blood and dialysate drug levels.
Discussion:  The study will develop improved dosing recommendations for intraperitoneally
administered gentamicin in PD patients with peritonitis. This will guide clinicians and pharmacists
in selecting the most appropriate dosing regime of intraperitoneal gentamicin to treat peritonitis.
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Background
Peritonitis is a major complication of PD and is one of the
main reasons why patients are transferred to haemodialy-
sis [1,2]. Antibiotics used to treat peritonitis may be deliv-
ered via the intraperitoneal (IP), intravenous (IV) or oral
routes. In most cases of PD related peritonitis, the infec-
tion is localised to the peritoneum and cells lining the
peritoneal cavity. The IP route of antibiotic administra-
tion is preferred because it ensures antibiotic concentra-
tions at the local site/s of the infection are maximised [3].
However, drugs administered intraperitoneally may still
be absorbed into the systemic circulation potentially lead-
ing to toxicity [4,5]. Peritonitis may also alter the permea-
bility of the peritoneal membrane with an inflamed
peritoneal membrane allowing increased absorption of
drugs from the peritoneal cavity into the blood stream
[6,7].
Most studies in this area have concentrated on the effec-
tiveness and outcomes of IP antibiotic therapy in PD
related peritonitis [8-13]. Only a few small studies have
reported the pharmacokinetics of antibiotics delivered via
the IP route [4,5,14-18]. Most were conducted in volun-
teer PD patients without peritonitis [4,5,16,18]. The
absorption and clearance of drugs administered intraperi-
toneally are not well described, particularly in pathologi-
cal states such as inflammation and infection. Poor or
absent renal excretion adds complexity to the pharmaco-
dynamics when drugs that reach the systemic circulation
and are excreted by the kidneys, such as gentamicin, are
used.
Gentamicin belongs to the aminoglycoside class of antibi-
otics and provides excellent coverage against Gram-nega-
tive bacteria. However, high blood levels are associated
with nephrotoxicity and ototoxicity. In the past, gen-
tamicin was not recommended for use in PD patients with
residual renal function due to the risk of causing it to fur-
ther decline [19]. A recent study has shown that the short
term use of aminoglycosides is safe and does not compro-
mise residual renal function [20]. This is reflected in the
current International Society for Peritoneal Dialysis
(ISPD) Guidelines/Recommendation for Peritoneal Dial-
ysis-Related Infections published in 2005 where gen-
tamicin is listed as one of the drug options for gram
negative empirical antibiotic cover [3]. The recommended
dose for intraperitoneal gentamicin in anuric patients is
0.6 mg/kg in a single dialysis bag administered once daily
and allowed to dwell for at least six-hours [3].
Aminoglycosides display concentration dependent bacte-
rial killing meaning maximal bacterial killing requires
high peak drug concentrations [21] and also have a pro-
longed post-antibiotic effect (PAE) where bacterial growth
continues to be inhibited even when the drug concentra-
tions fall below the minimum inhibitory concentration
[22]. Both the concentration dependent killing and the
PAE justify the recommendations for once-daily gen-
tamicin dosing [16,17]. IP antibiotic dosing according to
current guidelines gives rise to high gentamicin concentra-
tions in the peritoneal cavity for at least six-hours, which
increases the likelihood of systemic absorption and subse-
quent toxicity without additional antibacterial effect.
A gentamicin trough concentration of <2 mg/L is usually
recommended because early studies reported an increased
risk of toxicity with higher concentrations [23]. A recent
retrospective study from the UK found that the current
ISPD dosing guidelines for IP gentamicin resulted in high
trough plasma concentrations in over 50% of patients [9].
High plasma concentrations of gentamicin can not be rap-
idly removed by renal excretion in patients requiring PD
increasing the risk of toxicity. Monitoring of gentamicin
plasma concentrations in patients with renal impairment
is useful in avoiding drug accumulation and minimising
the possible toxicities of the drug, including loss of resid-
ual renal function.
This pharmacokinetic study of gentamicin was designed
to develop improved dosing guidelines to achieve optimal
bacterial kill, based on the performance of drug delivered
intraperitoneally to a population with poor or no renal
function.
Aims
To describe the pharmacokinetics of gentamicin adminis-
tered intraperitoneally in PD patients with peritonitis
using a population pharmacokinetic model; and To test
this pharmacokinetic model by computerised dosing sim-
ulations and subsequently develop dosing recommenda-
tions for IP gentamicin to optimise antibiotic efficacy and
minimise toxicity.
Methods/Design
Study Design
This is a pharmacokinetic study. Samples of blood, dia-
lysate fluid and urine will be collected from participants
presenting to the Royal Brisbane and Women's Hospital
(RBWH), diagnosed with PD peritonitis and treated
according to protocol, based on the current International
Society for Peritoneal Dialysis Peritonitis Treatment Rec-
ommendations.
Setting
The Department of Renal Medicine, RBWH services a pop-
ulation of approximately 1.2 million. This study is done
in collaboration with the Burns, Trauma and Critical Care
Research Centre, School of Medicine, The University of
Queensland.BMC Nephrology 2009, 10:42 http://www.biomedcentral.com/1471-2369/10/42
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Identification of Eligible Patients
Participants who present with clinically defined signs and
symptoms of peritonitis, as listed in Table 1, that fulfil the
inclusion and exclusion criteria will be eligible for the
study. Written informed consent will be obtained from
each participant.
Inclusion criteria
Male and female participants over 18 years of age, who
have been receiving Continuous Ambulatory Peritoneal
Dialysis (CAPD) or Automated Peritoneal Dialysis (APD)
for more than one-month, presenting to the Royal Bris-
bane and Women's Hospital (RBWH) Renal Medicine
Department with clinical evidence of peritonitis and
requiring treatment with IP gentamicin according to the
current RBWH protocol.
Exclusion criteria
Participants will be excluded if their peritonitis does not
require IP gentamicin based on the peritonitis protocol,
are pregnant, planning a pregnancy or if they have
received a course of antibiotics in the preceding two
weeks.
Participants
Participants will be stratified into two groups of 15 each
according to residual urine output.
Table 1: Explanation of definitions to be used as part of this study
Terms Definitions
Peritonitis * Presence of two clinical signs and symptoms:
abdominal pain, nausea, vomiting, diarrhoea, fever and cloudy dialysate
* Peritoneal dialysate WCC > 100/mm3 with 50% neutrophils
* Demonstration of bacteria on gram stain or culture
Clinical failure * Insufficient lessening of signs and symptoms of infection to qualify as improvement
* Continued symptoms or signs beyond day four
* Dialysate WCC > 100/mm3 at day 14
* Removal of the catheter for failure to respond to treatment
* Recurrence of peritonitis with same micro-organism (relapse) within 28-day follow up 
period after cessation of antibiotics
* Death due to uncontrolled infection
Clinical success Primary response - disappearance of the signs and symptoms of peritonitis and clear, 
sterile PD on day 10
Relapsed - primary response but recurrence by day 28
Complete cure - no relapse by day 28 after completion of antibiotics
Outcome indeterminate When no evaluation is possible for any reason
Bacteriologic response based on culture results Eradication -Causative organisms absent and remaining absent for 28 days after 
completion of antibiotics
Persistence - Causative organisms present at any culture dates after initiation of therapy
Superinfection - Presence of new infecting organisms and cultures dates during and just 
after two days of therapy
Bacteriologic indeterminate - When result not available for any reason including no 
growth in the first culture
Eradication with relapse - Causative organisms absent at day 14 but present at or 
before 28 +/- 2 days follow up
Eradication with reinfection - Causative organisms absent at day 14 and presence of 
new organisms at or before 28 +/- 2 days of follow up
Key: This is a list of suggested definitions for use in future research studies in this area- from the Caring for Australasians with Renal Impairment 
(CARI) Guidelines for PD associated peritonitis 2004BMC Nephrology 2009, 10:42 http://www.biomedcentral.com/1471-2369/10/42
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1. Anuric participants - with a urine output of less than 100
ml/day
2. Non-anuric participants - with a urine output of more
than 100 ml/day
This will be based on the most recent 24-hour urinary col-
lection done within the preceding six-month period. A
collaborating 24-hour urinary collection will be per-
formed, starting at the time of admission, to guide future
gentamicin dosing.
Drug dosing
Drug dosing will be based on the current International
Society for Peritoneal Dialysis Guidelines/Recommenda-
tions for Peritoneal Dialysis-Related Infections (2005).
The dose administered will depend on whether the partic-
ipant is anuric or non-anuric.
Anuric participants
0.6 mg/kg gentamicin in a single two-litre PD bag admin-
istered intraperitoneally once daily and allowed to dwell
for at least six-hours
Non-anuric participants
For this group of patients with residual renal function, the
dose of gentamicin will be increased by 25% - 0.75 mg/kg
for at least a six-hour dwell.
Sample collection
All participants will have blood sampling on two separate
days (day one and another day between day two and five
of treatment). A cannula will be placed for serial plasma
sampling and PD fluid will be collected as follows:
Sample collection on day one of treatment
Plasma samples (5 ml each) taken at one hour, three
hours, six hours, seven hours and 24 hours after the start
of draining in the first dialysate bag containing gen-
tamicin.
PD fluid samples (5 ml) will also be collected at three
hours and at the end of the dwell time at six hours.
Sample collection on one day between day two and five of treatment
Five millilitres of blood will be taken just prior to draining
in the dialysate with gentamicin to measure the true
'trough' gentamicin levels. A further 5 mls of blood will be
collected at one hour, three hours, six hours, seven hours
and 24 hours after the administration of the bag with IP
gentamicin. Five millilitres of PD fluid will also be col-
lected prior to administration of next bag of gentamicin,
at three hours and at the end of the dwell time. For each
dose of IP gentamicin administered, the type and volume
of dialysate and inflow rate of the dialysate loaded with
drug will be recorded. A 5 ml sample from the preceding
24-hour urine collection will be collected to measure the
concentration of gentamicin excreted in urine. Ten milli-
litre samples of PD fluid from each drained bag will also
be obtained before the dialysis effluent is discarded.
Sample handling and storage
Blood samples will be placed on ice and centrifuged at
3000 rpm before being stored at -80°C until analysis. Dia-
lysate and urine samples will be stored at -80°C until
analysis.
Sample analysis
The Burns Trauma and Critical Care Research Centre of
The University of Queensland will measure gentamicin
levels in plasma and dialysate using validated liquid chro-
matography tandem-mass spectrometry (LC-MS/MS) ana-
lytical assays.
Data collection
Additional data will be obtained by history from the par-
ticipant or extracted from the clinical notes. These
include:
1. Participant information - age, gender, weight, height,
allergies, cause of kidney disease, co-morbidities
2. Microbiology results - Gram stain, culture and antimi-
crobial sensitivities of dialysate fluid at admission to hos-
pital
3. Laboratory investigations - full blood count, electro-
lytes, coagulation profile, liver function test and C-reac-
tive protein at admission to hospital as part of usual care.
4. Date of start of this period of peritoneal dialysis
5. Previous dialysis history
6. Other antibiotics prescribed concomitantly
7. Other drugs prescribed concomitantly
8. Details of gentamicin therapy, including dosing regime
and duration
9. Length of stay in hospital
10. Outcome of treatment (clinical and/or bacteriological
success) will be described using the definitions listed in
Table 1
11. Renal function assessments -urine output measure-
ment, 24-hour urinary creatinine clearanceBMC Nephrology 2009, 10:42 http://www.biomedcentral.com/1471-2369/10/42
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Statistical considerations
A sample size calculation including a power calculation is
not required as this study is a non-interventional study
and is not intended to compare between different treat-
ments or interventions. The purpose of the study is to
identify significant covariates that describe the variability
in gentamicin pharmacokinetics in peritoneal dialysis
participants. A sample size of 30 is sufficient for this pop-
ulation pharmacokinetic study to identify most clinically
significant covariates. In general, population pharmacok-
inetic studies have fewer statistical design restrictions [24].
Data analysis
The results of sample analysis will be entered into the
pharmacokinetic computer software program NONMEM
(GloboMax LLC, Hanover, MD, USA) to develop a model
for gentamicin dosing via the intraperitoneal route. The
influence of demographic and clinical covariates, includ-
ing anuria, will be tested in the model. The model will
simulate gentamicin pharmacokinetics for different dos-
ing schedules to predict the best dosing recommendations
for intraperitoneal gentamicin in peritoneal dialysis par-
ticipants with peritonitis [25].
Ethical Considerations
The Human Research and Ethics Committee of the Royal
Brisbane and Women's Hospital (HREC/08/QRBW/8)
and the Medical Research Ethics Committee of the Uni-
versity of Queensland (2009000673) have approved this
study.
Withdrawal from Study
Participants may withdraw from the study anytime with-
out prejudice, as documented and explained at the time of
consenting.
Discussion
Multiple factors influence the absorption and clearance of
IP antibiotics in peritoneal dialysis patients with peritoni-
tis [24]. These include individual patient related variables
like membrane transport characteristics and residual renal
function, drug related factors such as the physicochemical
properties of the drug itself and factors relating to the dial-
ysis modality such as dialysate dwell time and the number
of exchanges. The pharmacokinetic model that will be
developed from this study will incorporate these factors
and the information will be used to conduct dosing simu-
lations of different antibiotic doses with different dwell
times to determine the most effective dosing regimen for
gentamicin delivered intraperitoneally. Optimised IP gen-
tamicin dosing can shift the balance of our therapeutic
interventions to maintain good clinical outcomes and
lesser toxicity in this high risk patient population.
Abbreviations
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